Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jerry Olson who wrote (74830)	12/9/1999 2:42:00 PM
From: Teri Garner	Respond to of 120523

Upcoming splits: EMLX, EXDS, ARBA, ICGE

To: Jerry Olson who wrote (74830)	12/9/1999 2:51:00 PM
From: kha vu	Read Replies (1) \| Respond to of 120523

CLPA: this is a very positive news for CLPA biz.yahoo.com <<<...Ninety-two of 96 enrolled patients were evaluable in this randomized double blind, placebo-controlled, multi-center trial. Of the 92 evaluable patients, 47 received placebo and 45 received Aptosyn. Results from the 92 evaluable patients showed that the rise in average PSA levels in the Aptosyn-treated group was significantly lower than that seen in the placebo-treated group. The company also performed a subgroup analysis in which patients were prospectively classified as high-, intermediate- and low-risk for developing metastatic disease. The one-year treatment data showed statistically significant differences in the rise in average PSA levels between Aptosyn and placebo patients in the high-risk group, and a strong trend toward significance in the intermediate risk group. The safety profile of Aptosyn was similar to those observed in previous clinical trials, with two patients discontinuing therapy due to indigestion. >>>

To: Jerry Olson who wrote (74830)	12/9/1999 2:52:00 PM
From: tracor	Read Replies (1) \| Respond to of 120523

OJ and all, Might try "old SI", Seems to have been working well for the last few days. RZ

To: Jerry Olson who wrote (74830)	12/9/1999 3:02:00 PM
From: red_dog	Read Replies (1) \| Respond to of 120523

moneycentral.msn.com

To: Jerry Olson who wrote (74830)	12/9/1999 5:35:00 PM
From: Michael Young	Read Replies (2) \| Respond to of 120523

<<i'm buying CLPA, Cell Pathways....cancer drug could get approval this month at the Fda...INCREDIBLE CHART, formed a full triangle, and if it prints 12/13 it will break to the upside...resolving itself to potential large numbers...>> I'm afraid you have your facts wrong. A competitive drug will appear before the FDA oncology panel in December. CLPA's drug was NOT selected for presentation. It appears likely they won't receive a panel review until March, but that is still unclear. MIKE